Prime Capital Investment Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.91M | Sell |
15,085
-967
| -6% | -$127K | 0.02% | 389 |
|
|
2026
Q1 | $2.24M | Sell |
16,052
-3,202
| -17% | -$448K | 0.03% | 343 |
|
|
2025
Q4 | $2.36M | Sell |
19,254
-534
| -3% | -$64.9K | 0.03% | 325 |
|
|
2025
Q3 | $2.2M | Sell |
19,788
-421
| -2% | -$47.9K | 0.03% | 324 |
|
|
2025
Q2 | $2.24M | Sell |
20,209
-5,169
| -20% | -$550K | 0.03% | 311 |
|
|
2025
Q1 | $2.84M | Buy |
25,378
+3,201
| +14% | +$330K | 0.03% | 305 |
|
|
2024
Q4 | $2.05M | Sell |
22,177
-2,654
| -11% | -$239K | 0.03% | 296 |
|
|
2024
Q3 | $2.08M | Sell |
24,831
-14,908
| -38% | -$1.14M | 0.03% | 304 |
|
|
2024
Q2 | $2.73M | Sell |
39,739
-9,233
| -19% | -$616K | 0.04% | 271 |
|
|
2024
Q1 | $3.59M | Sell |
48,972
-22,969
| -32% | -$1.77M | 0.05% | 248 |
|
|
2023
Q4 | $5.83M | Buy |
71,941
+39,558
| +122% | +$3.08M | 0.09% | 181 |
|
|
2023
Q3 | $2.43M | Sell |
32,383
-3,360
| -9% | -$258K | 0.05% | 230 |
|
|
2023
Q2 | $2.75M | Buy |
35,743
+15,961
| +81% | +$1.27M | 0.05% | 228 |
|
|
2023
Q1 | $1.64M | Sell |
19,782
-3,528
| -15% | -$292K | 0.07% | 187 |
|
|
2022
Q4 | $2M | Buy |
23,310
+14,086
| +153% | +$1.12M | 0.08% | 174 |
|
|
2022
Q3 | $569K | Buy |
9,224
+5,969
| +183% | +$376K | 0.03% | 223 |
|
|
2022
Q2 | $201K | Buy |
+3,255
| New | +$202K | 0.01% | 360 |
|
|
2021
Q2 | – | Sell |
-929
| Closed | -$60K | – | 441 |
|
|
2021
Q1 | $60K | Sell |
929
-438
| -32% | -$28.2K | ﹤0.01% | 323 |
|
|
2020
Q4 | $80K | Sell |
1,367
-50,738
| -97% | -$3.06M | 0.01% | 290 |
|
|
2020
Q3 | $3.29M | Sell |
52,105
-11,469
| -18% | -$795K | 0.28% | 70 |
|
|
2020
Q2 | $4.89M | Buy |
63,574
+62,397
| +5,301% | +$4.78M | 0.46% | 46 |
|
|
2020
Q1 | $88K | Buy |
1,177
+967
| +460% | +$66.8K | 0.01% | 253 |
|
|
2019
Q4 | $14K | Sell |
210
-2,188
| -91% | -$142K | ﹤0.01% | 457 |
|
|
2019
Q3 | $152K | Sell |
2,398
-32,819
| -93% | -$2.15M | 0.02% | 214 |
|
|
2019
Q2 | $2.38M | Sell |
35,217
-333
| -0.9% | -$21.9K | 0.43% | 69 |
|
|
2019
Q1 | $2.31M | Sell |
35,550
-7,027
| -17% | -$467K | 0.67% | 45 |
|
|
2018
Q4 | $2.66M | Buy |
42,577
+1,027
| +2% | +$71.8K | 0.97% | 28 |
|
|
2018
Q3 | $3.21M | Buy |
41,550
+11,915
| +40% | +$900K | 1.02% | 33 |
|
|
2018
Q2 | $2.1M | Buy |
29,635
+29,391
| +12,045% | +$2.08M | 0.88% | 38 |
|
|
2018
Q1 | $18K | Sell |
244
-35,056
| -99% | -$2.79M | 0.01% | 194 |
|
|
2017
Q4 | $2.53M | Buy |
+35,300
| New | +$2.68M | 1.95% | 17 |
|
Other funds holding GILD
Prime Capital Investment Advisors's GILD Position: Q2 2026 in Review
Prime Capital Investment Advisors reduced its Gilead Sciences (GILD) stake by 6% in Q2 2026, selling an estimated $127K and leaving 15,085 shares worth $1.91M. The position accounts for 0.02% of the portfolio, ranked #389.
Prime Capital Investment Advisors first reported a position in GILD in Q4 2017 and has held it in 31 quarters since. The position peaked at $5.83M in Q4 2023. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Prime Capital Investment Advisors held 15,085 shares of Gilead Sciences worth $1.91M as of Q2 2026.
- Prime Capital Investment Advisors sold 967 Gilead Sciences shares in Q2 2026, an estimated $127K.
- Gilead Sciences made up 0.02% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #389 holding.
- Prime Capital Investment Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 31 quarters since.
- Prime Capital Investment Advisors's Gilead Sciences position peaked at $5.83M in Q4 2023.
- 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.